CNBX Stock Overview
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CNBX Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.011 |
| 52 Week High | US$0.049 |
| 52 Week Low | US$0.0085 |
| Beta | 0.87 |
| 1 Month Change | -30.82% |
| 3 Month Change | 0.92% |
| 1 Year Change | -6.38% |
| 3 Year Change | -99.95% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.1% | 1.0% | -0.7% |
| 1Y | -6.4% | 11.6% | 22.3% |
Return vs Industry: CNBX underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CNBX underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| CNBX volatility | |
|---|---|
| CNBX Average Weekly Movement | 32.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CNBX's share price has been volatile over the past 3 months.
Volatility Over Time: CNBX's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2 | Eyal Barad | www.cnbxpharma.com |
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer.
CNBX Pharmaceuticals Inc. Fundamentals Summary
| CNBX fundamental statistics | |
|---|---|
| Market cap | US$457.34k |
| Earnings (TTM) | -US$1.23m |
| Revenue (TTM) | US$540.24k |
0.6x
P/S Ratio-0.3x
P/E RatioIs CNBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNBX income statement (TTM) | |
|---|---|
| Revenue | US$540.24k |
| Cost of Revenue | US$17.57k |
| Gross Profit | US$522.67k |
| Other Expenses | US$1.75m |
| Earnings | -US$1.23m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 96.75% |
| Net Profit Margin | -228.09% |
| Debt/Equity Ratio | -54.8% |
How did CNBX perform over the long term?
See historical performance and comparison